Hospital de Santa Maria-ko ikertzaileekin lankidetzan egindako argitalpenak (20)

2022

  1. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe

    HIV Medicine, Vol. 23, Núm. 6, pp. 684-692

  2. Observational cohort study of rilpivirine (RPV) utilization in Europe

    AIDS Research and Therapy, Vol. 19, Núm. 1

  3. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study

    HIV Medicine, Vol. 23, Núm. 6, pp. 585-598

2021

  1. Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort

    Journal of Acquired Immune Deficiency Syndromes, Vol. 87, Núm. 2, pp. 806-817

  2. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

    Annals of Internal Medicine, Vol. 174, Núm. 6, pp. 768-776

2018

  1. Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort

    HIV Medicine, Vol. 19, Núm. 4, pp. 252-260

2016

  1. Infection-related and -unrelated malignancies, HIV and the aging population

    HIV Medicine, Vol. 17, Núm. 8, pp. 590-600

  2. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study

    Medicine (United States), Vol. 95, Núm. 40

2015

  1. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

    HIV Medicine, Vol. 16, Núm. 9, pp. 533-543

  2. Liver-related death among HIV/hepatitis C virus-co-infected individuals: Implications for the era of directly acting antivirals

    AIDS, Vol. 29, Núm. 10, pp. 1205-1215

2014

  1. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

    Infection, Vol. 42, Núm. 4, pp. 757-762

  2. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study

    BMC Nephrology, Vol. 15, Núm. 1

  3. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study

    Journal of Infectious Diseases, Vol. 210, Núm. 3, pp. 354-362

  4. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe

    PLoS ONE, Vol. 9, Núm. 1

2013

  1. Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients

    PLoS ONE, Vol. 8, Núm. 5

2012

  1. Hepatitis c virus viremia increases the Incidence of chronic kidney disease in HIV-infected Patients

    AIDS, Vol. 26, Núm. 15, pp. 1917-1926

  2. Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: The EuroSIDA study

    PLoS ONE, Vol. 7, Núm. 7

2011

  1. A376s in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy

    Journal of Infectious Diseases, Vol. 204, Núm. 5, pp. 741-752

2010

  1. Dialysis and renal transplantation in HIV-infected patients: A European survey

    Journal of Acquired Immune Deficiency Syndromes, Vol. 55, Núm. 5, pp. 582-589

2006

  1. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-Week results of the RESIST-2 trial

    Clinical Infectious Diseases, Vol. 43, Núm. 10, pp. 1347-1356